



ten23 health® and Neumirna Therapeutics team up to develop RNA therapy for epilepsy

The partnership aims to accelerate clinical translation of NMT.001, a microRNA-targeting RNA therapy for drug-resistant epilepsy.

Basel, Switzerland–October 27, 2025: ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, is excited to announce its collaboration with Neumirna Therapeutics ('Neumirna'), a biotechnology company developing RNA-based therapies for neurological diseases. The two companies will collaborate to advance NMT.001, a microRNA-targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring the therapy into clinical trials, combining ten23's formulation and manufacturing expertise with Neumirna's RNA innovation.

"We are honored to collaborate with Neumirna Therapeutics and support their mission to address critical medical needs through innovative healthcare solutions," said Dr. Susanne Jörg, COO of ten23 health. *"Our expertise and ongoing research in drug product development, manufacturing, and testing of oligonucleotide therapies, including RNA, align seamlessly with Neumirna's commitment to delivering life-changing therapies. We share a common goal of improving patient care, and look forward to advancing this program effectively and efficiently."*

"Partnering with ten23 health strengthens our ability to accelerate the development of our pipeline while maintaining the highest standards of quality," said Dr. Ellen Donnelly, CEO at Neumirna Therapeutics. *"Their proven track record and expertise support our vision of bringing novel therapies to patients in need. Together, we are taking a decisive step forward in advancing healthcare innovation."*

The partnership arrives at a time of growing momentum for RNA and oligonucleotide-based therapies, particularly in areas with limited treatment options, such as chronic neurological diseases. ten23's integrated services – spanning development, manufacturing, and testing – will enable faster and more robust advancement of complex therapies, and support biotechs like Neumirna on their path to commercialization.

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.



ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

About Neumirna Therapeutics

Neumirna Therapeutics is a biotechnology company based in Copenhagen, Denmark, dedicated to developing RNA-based therapies for complex neurological diseases. With a proprietary platform targeting antisense oligonucleotides (ASO-LNAs), Neumirna is advancing a pipeline of therapies for patients with high unmet medical needs, including drug-resistant epilepsy and Parkinson's disease. For more information, visit www.neumirna.com.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com

Neumirna Therapeutics: Shideh Morovati, shm@neumirna.com